Skip to main content
SpringerLink
Log in

Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Deficient expression of HLA class-I molecules observed in many cancers is suggested to influence both disease progression and potential efficacy of T cell-mediated immune therapy. Previous studies have attempted to correlate either primary breast cancer tumor grade with HLA class-I levels or the presence of HLA class-I-deficient cells in metastatic lesions with survival. In this study we evaluated the HLA class-I status of matched primary and secondary breast cancer lesions in order to ask the question: is metastasis of breast cancer associated with down-regulation of HLA class-I expression? Immunocytochemistry analysis shows a definitive correlation between diminished HLA class-I expression and dissemination of breast cancer to tumor-draining lymph nodes: both the total number of HLA class-I+ cells per sample and the levels of expression are dramatically decreased in secondary versus primary tumor lesions. These findings are consistent with the contention that the ability of breast cancer cells to escape the confines of the original tumor lesion requires down-regulation of HLA class-I expression and implies that enhancing HLA class-I expression in secondary breast cancer may have a beneficial effect on T-cell-mediated immunotherapy.

Abbreviations: LN – lymph node; TAP – transporters associated with antigen processing

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ogmundsdottir HM, Petursdottir I and Gudmundsdottir I Interactions between the immune system and breast cancer. Acta Oncol 1995; 34: 647–50.

    PubMed  CAS  Google Scholar 

  2. Ogmundsdottir HM Immune reaction to breast cancer: for better or for worse? Arch Immunol Ther Exp (Warsz) 49 2001; S75–81.

    Google Scholar 

  3. Hicklin DJ, Marincola FM and Ferrone S. HLA class-I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999; 5: 178–86.

    Article  PubMed  CAS  Google Scholar 

  4. Levin I, Klein T, Goldstein J, Kuperman O, Kanetti J and Klein B. Expression of class-I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 1991; 68: 2591–4.

    Article  PubMed  CAS  Google Scholar 

  5. Zia A, Schildberg FW and Funke I. MHC class-I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 2001; 93: 566–70

    Article  PubMed  CAS  Google Scholar 

  6. Concha A, Cabrera T, Ruiz-Cabello F and Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl 1991; 6: 146–54.

    CAS  Google Scholar 

  7. Wintzer HO, Benzing M and von Kleist S. Lacking prognostic significance of beta 2-microglobulin, MHC class-I and class-II antigen expression in breast carcinomas. Br J Cancer 1990; 62: 289–95.

    PubMed  CAS  Google Scholar 

  8. Ruiz-Cabello F, Lopez Nevot MA, Gutierrez J et al. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Metast 1989; 7: 213–26.

    Article  CAS  Google Scholar 

  9. Goepel JR, Rees RC, Rogers K et al. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br J Cancer 1991; 64: 880–3.

    PubMed  CAS  Google Scholar 

  10. Maiorana A, Cesinaro AM, Fano RA and Collina G. Expression of MHC class-I and class-II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metast 1995; 13: 43–8.

    Article  CAS  Google Scholar 

  11. Kaklamanis L, Leek R, Koukourakis M et al. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class-I molecules in metastatic versus primary breast cancer. Cancer Res 1995; 55: 5191–4.

    PubMed  CAS  Google Scholar 

  12. Vitale M, Rezzani R, Rodella L et al. HLA class-I antigen and transporter associated with antigen processing (TAP1 and TAP2) downregulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737–42.

    PubMed  CAS  Google Scholar 

  13. Sykulev Y, Joo M, Vturina I et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T-cell response. Immunity 1996; 4: 565–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Masanao Saio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matt Teicher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaynor Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen Feiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yara Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alan B. Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saio, M., Teicher, M., Campbell, G. et al. Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma. Clin Exp Metastasis 21, 243–249 (2004). https://doi.org/10.1023/B:CLIN.0000037707.07428.ff

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CLIN.0000037707.07428.ff

Search

Navigation